Switching from Mixtard 30/70 to Weekly Insulin Icodec
For a patient on Mixtard 36 units morning and 24 units evening (total 60 units/day), calculate the initial weekly icodec dose as 420 units (60 × 7), and for faster glycemic control, administer 630 units for the first week only (420 × 1.5, rounded to 630 units), then reduce to 420 units weekly from week 2 onwards. 1
Important Caveat: Mixtard is NOT Pure Basal Insulin
Critical consideration: Mixtard 30/70 is a biphasic insulin containing 30% rapid-acting and 70% intermediate-acting insulin—it is NOT a pure basal insulin. The guideline recommendations are specifically designed for switching from once-daily or twice-daily basal insulin only 1. When switching from Mixtard, you must account for the fact that approximately 30% of the total daily dose is providing prandial (mealtime) coverage.
Recommended Approach
Step 1: Calculate the Basal Component
- Total daily Mixtard dose: 60 units (36 + 24)
- Approximate basal component: 42 units/day (70% of 60 units)
- The remaining 18 units (30%) was providing prandial coverage
Step 2: Initial Icodec Dosing Options
Option A - Conservative approach (recommended):
- Calculate based on basal component only: 42 units × 7 = 294 units/week
- With 50% loading dose for week 1: 294 × 1.5 = 441 units (round to 440 units)
- From week 2 onwards: 294 units weekly (round to 290 units)
- Add mealtime insulin (rapid-acting insulin aspart or lispro) to replace the lost prandial coverage, starting with approximately 4-6 units per main meal
Option B - If continuing without prandial insulin:
- Use full Mixtard dose: 60 units × 7 = 420 units/week
- With 50% loading dose for week 1: 420 × 1.5 = 630 units
- From week 2 onwards: 420 units weekly
- Monitor closely for postprandial hyperglycemia
Step 3: Loading Dose Decision
The 50% one-time additional dose for the first injection achieves steady state in 2-3 weeks versus 3-4 weeks without it 1. However, you may omit the loading dose if:
- The patient frequently misses insulin doses (may overestimate actual insulin need) 1
- The patient has hypoglycemia unawareness or history of severe hypoglycemia 1
- The patient is elderly, has renal/hepatic impairment, or low body weight 1
- The patient has preserved insulin sensitivity 1
Step 4: Monitoring and Titration
Monitoring requirements:
- Measure prebreakfast self-measured blood glucose (SMBG) at least 3 times per week
- Target range: 80-130 mg/dL (4.4-7.2 mmol/L) 1
- Begin titration from week 2 (if no loading dose) or week 3 (if loading dose used) 1
Titration strategy:
- Adjust by ±20 units weekly based on three prebreakfast SMBG values (2 days prior and day of next injection) 1
- If any value is below target range, use the lowest value for titration decision
- If all values are above target range, use the mean of three measurements 1
- For high-risk patients (elderly, renal/hepatic impairment), consider more conservative titration in 10-unit increments 1
Critical Safety Warnings
Avoid dosing errors:
- Do NOT continue the 50% loading dose beyond the first injection—this is the most common error and can cause severe hypoglycemia 1
- Ensure patient understands the dose reduction from week 2 onwards
- The icodec pen allows minimum adjustments of 10 units 1
Hypoglycemia risk:
- Exercise caution in patients with hypoglycemia unawareness, recurrent severe hypoglycemia, or cardiovascular disease within 180 days 1
- Rates of clinically significant hypoglycemia with icodec are generally comparable to daily basal insulins in type 2 diabetes 1
Special populations:
- Asian patients: Consider lower starting doses (30-70 U/week per local labels) 1
- Low BMI or chronic kidney disease: Consider starting at 50 U/week 1
- High insulin resistance or elevated HbA1c: May require higher doses 1
The Prandial Coverage Gap
This is the most important clinical consideration: By switching from Mixtard to icodec alone, you are removing approximately 18 units/day of prandial insulin coverage. This will likely result in postprandial hyperglycemia unless you add mealtime rapid-acting insulin. The ONWARDS trials specifically studied switches from basal insulin only, not from premixed insulins 1.
Strongly consider: Adding rapid-acting insulin (aspart, lispro, or glulisine) with meals, starting with 4-6 units per main meal and titrating based on 2-hour postprandial glucose targets of <180 mg/dL (<10.0 mmol/L).